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ABSTRACT 
RECQL5 is a member of the RecQ family of DNA helicases and has key roles in homologous 
recombination, base excision repair, replication and transcription. The clinicopathological 
significance of RECQL5 expression in breast cancer is unknown. In the current study we have 
evaluated RECQL5 mRNA expression in 1977 breast cancers, and RECQL5 protein level in 
1902 breast cancers [Nottingham Tenovus series (n=1650) and ER- cohort (n=252)]. 
Expression levels were correlated to aggressive phenotypes and survival outcomes. High 
RECQL5 mRNA expression was significantly associated with high histological grade 
(p=0.007), HER2 overexpression (p=0.032), ER+/HER2-/high proliferation genefu subtype, 
integrative molecular clusters (intClust 1and 9) and poor breast cancer specific survival (BCSS) 
(ps<0.0001). In sub-group analysis, high RECQL5 mRNA level remains significantly 
associated with poor BCSS in ER+ cohort (p<0.0001) but not in ER- cohort (p=0.116). At the 
protein level, in tumours with low RAD51, high RECQL5 level was significantly associated 
with high histological grade (p<0.0001), higher mitotic index (p=0.008), de-differentiation (p= 
0.025), pleomorphism (p= 0.027) and poor BCSS (P=0.003). In sub-group analysis, high 
RECQL5/low RAD51 remains significantly associated with poor BCSS in ER+ cohort 
(p=0.010), but not in ER- cohort (p=0.628). In multivariate analysis, high RECQL5 mRNA and 
high RECQL5/low RAD51 nuclear protein co-expression independently influenced BCSS (p 
= 0.022) in whole cohort and in the ER+ sub-group. Pre-clinically, we show that exogenous 
expression of RECQL5 in MCF10A cells can drive proliferation supporting an oncogenic 
function for RECQL5 in breast cancer. We conclude that RECQL5 is a promising biomarker 
in breast cancer. 
 
Summary: RECQL5 is a member of the RecQ family of DNA helicases and has key roles in 
homologous recombination, base excision repair, replication and transcription. We provide 
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the first clinical evidence that RECQL5 overexpression is associated with aggressive breast 
cancers. 
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INTRODUCTION 
 
RecQ helicases are a highly conserved family of proteins with critical roles in the maintenance 
of genomic stability (1-4). RECQL5 is a key member of the mammalian RecQ helicase family 
(1).  It is a 3’-5’ helicase with weak Holiday junction unwinding activity (1). RECQL5 
preferentially unwinds the lagging strand of DNA at replication fork structures and can promote 
strand exchange in vitro (5). Three isoforms of RECQL5 have been identified; RECQL5α 
(410aa), RECQL5β (435aa) and RECQL5γ (991aa) (6). Whereas RECQL5α and RECQL5γ 
are cytoplasmic, RECQL5β isoform has nuclear localisation (6). RECQL5β (here in referred 
to as RECQL5) interacts with multiple DNA repair and metabolising proteins including 
RAD51, RAD50, PARP1, FEN1, RNA Polymerase II, WRN, BLM and Mre11, NBS1, PCNA, 
TopIIa and Top IIIa/b (1). RECQL5 has important roles in homologous recombination (HR), 
base excision repair (BER), DNA replication and transcription (1). Evidence for a role in HR 
includes findings that RECQL5 deficient cells have an increased rate of sister chromatid 
exchange (7), and that depleted cells accumulate H2Ax and RAD51 foci (8). Mechanistically 
RECQL5’s function in HR can be proposed from in vitro studies showing that RECQL5 
physically interacts with RAD51, causing an ATPase dependent disruption of RAD51 
mediated presynaptic filament formation and hence has anti-recombinase activity (9) similar 
to Bloom syndrome helicase (BLM) (7). Further RECQL5 associates with the MRN complex 
and inhibits MRE11 exonuclease activity (10), which may also contribute to the HR function 
of RECQL5. Interestingly while the MRN complex is required to bring RECQL5 to sites of 
DSBs it’s recruitment is independent of the helicase activity (11). RECQL5 may also have a 
role in base excision repair (BER). It’s precise function in this pathway is not clear but 
RECQL5 interacts with the long patch BER proteins PCNA and FEN1, it’s interaction 
stimulating FEN1 activity, and RECQL5 co-localises with FEN1 after oxidative damage of 
DNA (12). In addition the short patch BER protein XRCC1 is retained at sites of oxidative 
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damage in the absence of RECQL5 and expression of PARP1 and XRCC1 maybe regulated by 
RECQL5 (13). A role in protecting cells from DNA replication stress has also been shown for 
RECQL5. RECQL5 foci increase following replication stress and overexpressing RECQL5 can 
overcome thymidine induced replication stress (14). Likewise RECQL5 can prevent 
spontaneous replication fork collapse and RECQL5 depleted cells are hypersensitive the DNA 
replication inhibitor camptothecin, (15, 16). RECQL5 has also been implicated in regulation 
of transcription elongation and can supress genomic instability associated with transcriptional 
stress (2, 17, 18).   
 
Germline mutation of three of the RecQ helicases (BLM, WRN and RECQL4) leads to cancer 
predisposition syndromes namely Bloom syndrome, Werner syndrome and Rothmund-
Thomson syndrome (3, 4). Although RECQL5 helicase has not been associated with any 
disease phenotype, in preclinical studies, RECQL5 deficient mice cells show increased levels 
of spontaneous double strand breaks, are susceptible to gross chromosomal rearrangements and 
are prone to develop lymphomas and various solid tumours including breast cancer (8) (19).  
 
 
We hypothesised that RECQL5 may influence breast cancer pathogenesis. In the current study 
we have evaluated RECQL5 mRNA expression in 1950 breast cancers, and RECQL5 protein 
level in 1902 breast cancers. We provide the first clinical evidence that RECQL5 may influence 
the development of aggressive breast cancer and have prognostic significance particularly in 
ER+ breast cancers. In addition we show that exogenous expression of RECQL5 in MCF10A 
cells can drive proliferation supporting a oncogenic function for RECQL5 in breast cancer. 
MATERIALS AND METHODS 
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RECQL5 and mRNA expression: RECQL5 mRNA expression was investigated in 
METABRIC (Molecular Taxonomy of Breast Cancer International Consortium) cohort. The 
METABRIC study protocol, detailing the molecular profiling methodology in a cohort of 
1980 breast cancer samples is described by Curtis et al (20).  Patient demographics are 
summarized in supplementary Table S1 of supporting information. ER positive and/or 
lymph node negative patients did not receive adjuvant chemotherapy.  ER negative and/or 
lymphnode positive patients received adjuvant chemotherapy. For   this   cohort, the mRNA 
expression   was   hybridized   to   Illumina   HT-12 v3 platform (Bead Arrays), and the data 
were pre-processed and normalized as described previously (20). RECQL5 expression was 
evaluated in this data set (RECQL5 probe ID: ILMN_1697682).  The probe was a perfect 
match and quality for its target, having a GC content of 58% , 0 SNPs and it does not possess 
a polyG tail at the end.  Samples were classified into the intrinsic subtypes based on the 
PAM50   gene   list. A   description   of   the   normalization, segmentation, and statistical 
analyses was previously described (20).   Real time RT-qPCR was performed on the ABI 
Prism 7900HT sequence detection system   (Applied   Biosystems)   using   SYBR1 Green   
reporter.   All   the samples were analysed as triplicates. The Chi-square test was used for 
testing association between categorical variables, and a multivariate Cox model was fitted to 
the data using as endpoint breast cancer specific death.  Xtile (Version 3.6.1) was used to 
identify a cut-off in gene expression values such that the resulting subgroups have 
significantly different survival courses. In addition, a corrected P-value was produced for 
each analysis by  using  Monte-Carlo  Cross Validation (MCCV) simulations ( 50 random 
populations) in X-tile to avoid the problem of  over fitting and finding aberrantly low p-value 
due to the analysis of multiple cut-points (Camp et al,2004) . The two- fold cross validation  
was used to randomly split the data in to two halves and find the optimal cut-point of 
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one half, and then divide the other half according to this cut-point. Then, the optimal cut-
point of the second half  was found and the first halve was similarly divided. Finally, a 
survival analysis of the entire dataset  was performed based on the average of the  optimal 
cut-points obtained from the MCCV simulations (Camp et al ,2004).  
RECQL5 protein expression in breast cancer: The study was performed in a consecutive 
series of 1650 patients with primary invasive breast carcinomas who were diagnosed between 
1986 and 1999 and entered into the Nottingham Tenovus Primary Breast Carcinoma series.  
Patient demographics are summarised in Supplementary Table S2. This is a well-
characterized series of patients with long-term follow-up that have been investigated in a wide 
range of biomarker studies (21-24).  All patients were treated in a uniform way in a single 
institution with standard surgery (mastectomy or wide local excision), followed by 
Radiotherapy.   Prior to 1989, patients did not receive systemic adjuvant treatment (AT). After 
1989, AT was scheduled based on prognostic and predictive factor status, including 
Nottingham Prognostic Index (NPI), oestrogen receptor-α (ER-α) status, and menopausal 
status. Patients with NPI scores of <3.4 (low risk) did not receive AT. In pre-menopausal 
patients with NPI scores of ≥3.4 (high risk), classical Cyclophosphamide, Methotrexate, and 
5-Flurouracil (CMF) chemotherapy was given; patients with ER-α positive tumours were also 
offered endocrine therapy. Postmenopausal patients with NPI scores of ≥3.4 and ER-α 
positivity were offered endocrine therapy, while ER-α negative patients received classical CMF 
chemotherapy. Median follow up was 111 months (range 1 to 233 months).  Survival data, 
including overall survival, disease-free survival (DFS), and development of loco-regional and 
distant metastases (DM), was maintained on a prospective basis.  DFS was defined as the 
number of months from diagnosis to the occurrence of local recurrence, local lymph node (LN) 
relapse or DM relapse.  Breast cancer specific survival (BCSS) was defined as the number of 
months from diagnosis to the occurrence of BC related-death. Local recurrence free survival 
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(LRS) was defined as the number of months from diagnosis to the occurrence of local 
recurrence. DM-free survival was defined as the number of months from diagnosis to the 
occurrence of DM relapse.  Survival was censored if the patient was still alive at the time of 
analysis, lost to follow-up, or died from other causes. 
We also evaluated an independent series of 252 ER-α negative invasive BCs diagnosed and 
managed at the Nottingham University Hospitals between 1999 and 2007.  All patients were 
primarily treated with surgery, followed by Radiotherapy and anthracycline chemotherapy. The 
characteristics of this cohort are summarised in supplementary Table S3.  
Tumor Marker Prognostic Studies (REMARK) criteria, recommended by McShane et al (25), 
were followed throughout this study.  Ethical approval was obtained from the Nottingham 
Research Ethics Committee (C202313).  
Tissue Microarrays (TMAs) and immunohistochemistry (IHC): Tumours were arrayed in 
tissue microarrays (TMAs) constructed with 2 replicate 0.6mm cores from the centre and 
periphery of the tumours. The TMAs were immunohistochemically profiled for RECQL5 and 
other biological antibodies (Supplementary Table S4 of supporting information) as 
previously described (21-24).  Immunohistochemical staining was performed using the Thermo 
Scientific Shandon Sequenza chamber system (REF: 72110017), in combination with the 
Novolink Max Polymer Detection System (RE7280-K: 1250 tests), and the Leica Bond 
Primary Antibody Diluent (AR9352), each used according to the manufacturer’s instructions 
(Leica Microsystems).  Leica Autostainer XL machine was used to dewax and rehydrate the 
slides. Pre-treatment antigen retrieval was performed on the TMA sections using sodium citrate 
buffer (pH 6.0) and heated for 20 minutes at 950C in a microwave (Whirpool JT359 Jet Chef 
1000W). A set of slides were incubated for 60 minutes with the primary anti-RECQL5 antibody 
(HPA029971, Sigma-Aldrich, UK) and anti-RAD51 antibody (clone Ab88572, Abcam Ltd., 
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Cambridge, UK), at a dilution of 1:100 and 1:70 respectively. Negative and positive (by 
omission of the primary antibody and IgG-matched serum) controls were included in each run. 
The negative control ensured that all the staining was produced from the specific interaction 
between antibody and antigen. 
 
Evaluation of immune staining: The tumour cores were evaluated by two scorers (AA and 
TAF) and the concordance between the two scorer was excellent (k = 0.79). Whole field 
inspection of the core was scored and intensities of nuclear staining were grouped as follows: 
0 = no staining, 1 = weak staining, 2 = moderate staining, 3 = strong staining. The percentage 
of each category was estimated (0-100%).  H-score (range 0-300) was calculated by 
multiplying intensity of staining and percentage staining. RECQL5, RAD51 and TOPO2A 
expression was categorised based on the frequency histogram distributions. A median H score 
of ≥10 was taken as the cut-off for high RECQL5 and a median H score of ≥8 was taken as the 
cut-off for high RAD51 nuclear expression. For TOPO2A >25% staining cells were taken as 
high TOPO2A expression. Not all cores within the TMA were suitable for IHC analysis as 
some cores were missing or lacked tumour (<15% tumour).  
Statistical analysis: Data analysis was performed using SPSS (SPSS, version 17 Chicago, IL). 
Where appropriate, Pearson’s Chi-square, Fisher’s exact, Student’s t and ANOVA one way 
tests were used. Cumulative survival probabilities were estimated using the Kaplan–Meier 
method, and differences between survival rates were tested for significance using the log-rank 
test. Multivariate analysis for survival was performed using the Cox proportional hazard model. 
The proportional hazards assumption was tested using standard log-log plots. Hazard ratios 
(HR) and 95% confidence intervals (95% CI) were estimated for each variable. All tests were 
two-sided with a 95% CI and a p value <0.05 considered significant.  For multiple comparisons, 
p values were adjusted according to Holm-Bonferroni correction method (26).  
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Breast cancer cell lines and culture: MCF-7 (ER+/PR+/HER2-, BRCA1 proficient), MDA-
MB-231 (ER-/PR-/HER2-, BRCA1 proficient), MDA-MB-468 (ER-/PR-/HER2-, BRCA1 
proficient)  and MDA-MB-436 (ER-/PR-/HER2-, BRCA1 deficient) authenticated cell lines 
were purchased from ATCC and were grown in RPMI (MCF-7, MDA-MB-231) or DMEM 
(MDA-MB-468 and MDA-MB-436) medium with the addition of 10% foetal bovine serum 
and 1% penicillin/streptomycin. Cell lysates were prepared and Western blot analysis 
performed.  Primary anti-RECQL5 antibody (HPA029971, Sigma-Aldrich,UK) was incubated 
over night at room temperature at a dilution of 1:2000. Primary anti-β actin antibody (1:10000 
dilution [Abcam]) was used as a loading control. Infrared dye-labelled secondary antibodies 
(Li-Cor) [IRDye 800CW Mouse Anti-Rabbit IgG and IRDye 680CW Rabbit Anti-Mouse IgG] 
were incubated at a dilution of 1:10000 for 1 hour.  Membranes were scanned with a Li-Cor 
Odyssey machine (700 and 800nm) to determine protein expression.  
 
RECQL5 knockdown breast cancer cells using siRNAs: MCF7 cells were transfected with 
50 nM RECQL5 siRNA (Dharmacon, Lafayette, CO) using DharmaFECT 1 reagent 
(Dharmacon, Lafayette, CO) and left for 48 hours.  The cell lysates were prepared and western 
blotted for RECQL5 as above but immunoreactive protein was visualized using ECL reagents 
(Amersham Pharmacia) following manufacturer’s instructions.  The sequences used for Q5β-
1 and Q5β-3 siRNA constructs were 5’-UGAAGAAGGUGGCCGAUAU-3’ and 5’-
CUGCAAAUGUUGUGGUCAA-3’ respectively. 
 
RECQL5 overexpression in MCF10A cells and proliferation assay: 10,000 MCF10A cells 
were plated into replica wells of 6 well plate and transfected with pcDNA-RECQL5β (a 
generous gift from Dr. Pavel Janscak - Institute of Molecular Cancer Research, University of 
Zurich) or empty vector control. Following trypsinisation to remove cells from the plate live 
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cells counted every 24 h post transfection using trypan blue exclusion. In parallel cell lysates 
were prepared and western blotted for RECQL5 as above but immunoreactive protein was 
visualized using ECL reagents (Amersham Pharmacia) following manufacturer’s instructions. 
Quantitative real time PCR: Total RNA was extracted from MCF-7, MDA-MB-231, MDA-
MB-468 and MDA-MB-436 cells using RNeasy Mini kit (QIAGEN, UK). The quantification 
of the extracted RNA was done using a NanoDrop 2000c Spectrophotometer (Thermo 
Scientific, UK). The cDNA was synthesized from 0.5 μg of total RNA using RT2 first strand 
kit (QIAGEN, UK). qPCR was performed using SYBR Green PCR Master mix (applied 
biosystems,Warrington,UK) with primer set (RECQL5 QuantiTect Prier Assay,Cat. No. 
QT00084973, QIAGEN) targeting RECQL5 gene. The glyceraldehyde-3-phosphate 
dehydrogenase housekeeper gene was used as an internal control (GAPDH QuantiTect Prier 
Assay, Cat. No. QT00079247, QIAGEN). The real-time PCR for each RNA sample was 
performed in triplicate. NTC (No Template Control) was used to rule out cross contamination 
of reagents and surfaces. NTC included all the RT-PCR reagents except the RNA template. 
Minus reverse transcriptase (- RT) control was used to rule out genomic DNA contamination. 
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RESULTS 
 
High RECQL5 mRNA levels associate with aggressive sporadic breast cancer: We initially 
profiled a panel of breast cancer cell lines. MDA-MB-436, MDA-MB-468 MCF-7 and MDA-
MB 231 have robust expression of RECQL5 mRNA (Figure 1A). We then proceeded to 
investigate RECQL5 mRNA expression in the METABRIC cohort.  1306/1977 (6%) of breast 
tumours had low RECQL5 mRNA expression and 34% (671/1977) of breast tumours had high 
RECQL5 mRNA expression. High RECQL5 mRNA expression was significantly associated 
with aggressive clinicopathological features including high histological grade, HER2 over 
expression, and triple negative phenotypes (ps<0.05) [Table 1]. High RECQL4 mRNA 
expression was also found to be significantly correlated to previously described breast cancer 
molecular phenotypes; PAM50.Her2 (p<0.0001) and Genufu subtype (ER+/Her2-/High 
proliferation) (p<0.01) breast tumours [Table 1]. On the other hand, PAM50.LumA and 
Genufu subtypes (ER+/Her2-/low proliferation) were associated with low levels of RECQL5 
mRNA (ps<0.05) [Table 1]. Interestingly, PAM50.Basal was also more common in tumours 
with low levels of RECQL5 mRNA (ps<0.05). Similarly, low RECQL5 mRNA expression was 
associated with intClust.3 (p<0.00001) and intClust.4 (ps<0.001) molecular phenotypes that 
have good prognosis (27). However, high RECQL5 mRNA expression was significantly 
associated with intClust.1 (p<0.00001), and intClust.9 (p<0.00001) that have intermediate to 
poor clinical outcome (20).  
 
We then proceeded to survival analysis in METABRIC cohort. High RECQL5 mRNA 
expression was associated with poor breast cancer specific survival (BCSS) (p<0.0001) in the 
whole cohort [Figure 1B]. In the ER+ sub-group, high RECQL5 mRNA expression was found 
to be associated with poor BCSS (p<0.0001) [Figure 1C]. In the ER+ sub-group that received 
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adjuvant endocrine therapy, high RECQL5 mRNA expression remained associated with poor 
BCSS (p<0.001) [Figure 1D]. However, in ER- sub-group, RECQL5 mRNA expression did 
not significantly influence outcome in the ER- cohort, including ER- patients who received 
chemotherapy (p=0.116 and p=0.213 respectively) [Figure 1E, 1F].  
 
In the multivariate Cox regression analysis, that included other validated prognostic factors, 
RECQL5 mRNA expression was a powerful independent predictor for breast cancer specific 
survival in the whole cohort (p=0.038), ER+ sub-group (p=0.046) but not in the ER- sub-group 
(p=0.615) (Table 2).  
 
Together the data provides evidence that RECQL5 mRNA level has clinicopathological 
significance and influence prognosis, particularly in ER+ breast cancers. We proceeded to 
evaluate RECQL5 protein expression in breast cancers. 
 
RECQL5 protein expression in sporadic breast cancer: We initially investigated RECQL5 
protein level in breast cancer cell lines and in MCF10A breast epithelial cells. As shown in 
Figure 2A, MDA-MB-436, MDA-MB-468 MCF-7 and MDA-MB 231 have robust expression 
of RECQL5 protein.  On the other hand, in MCF10A cells, RECQL5 expression was low 
compared to MCF7 cells (Figure 2B). When RECQL5 was overexpressed in MCF10A (Figure 
2B) we observed increased proliferation in RECQL5 overexpressing MCF10A cells compared 
to control MCF10A cells (Figure 2C). Taken together, the data suggest that RECQL5 is a 
marker of proliferation and could have prognostic and/or predictive significance in human 
breast cancers. We proceeded to IHC investigation in human tumours. To provide evidence for 
the specificity of the anti-RECQL5 antibody used for IHC studies, we generated RECQL5 
knockdown (KD) MCF7 cells using two siRNA constructs. As shown in Figure 2D, control 
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cells have robust RECQL5 expression seen as a single band while RECQL5 KD cells show 
almost complete loss of this band – demonstrating the specificity of the RECQL5 antibody.  
 
We observed nuclear only localization of RECQL5 protein in breast cancers [Figure 2D]. 
There was no cytoplasmic staining in breast tumours. We initially investigated RECQL5 
protein alone. 46.3% (556/1200) of tumours showed low nuclear RECQL5 expression and 
53.7% (644/1200) of tumours revealed high nuclear RECQL5 expression. Tumours with low 
nuclear RECQL5 levels were significantly associated with high grade, high mitotic index, 
tubule formation, tumour type, HER2 overexpression, ER-, triple negative and basal type 
phenotype (ps<0.05) [Supplementary Table 5] . In addition, low RECQL5 expression was 
found to be associated with low levels of other DNA repair proteins such as BRCA1, XRCC1, 
FEN1, SMUG1, APE1, Polβ, ATM, ATR, Chk1, Chk2, TOP2A, Rad51, and DNA-PKc (ps< 
0.01) [Supplementary Table 5]. We then conducted the univariate survival analysis. At 
protein level, RECQL5 expression alone failed to show any statistically significant correlation 
with breast cancer specific survival in whole cohort [Supplementary Figure S1A]. We then 
proceeded to subgroup analysis and again found no statistically significant association with 
survival in ER+ [Supplementary Figure S1B] and ER- subgroups [Supplementary Figure 
S1C]. As RECQL5 alone, despite having clinicopathological associations with aggressive 
phenotype, did not have prognostic significance we hypothesised that RECQL5 may operate 
in the context of RAD51 or TOPO2A to influence clinical outcomes. We therefore proceeded 
to co-expression analysis.  
 
RECQL5 co-expression with RAD51 or TOPO2A in sporadic breast cancer: RECQL5 
physically interacts with RAD51 and disrupts RAD51 mediated presynaptic filament formation 
(1, 9). Tumours with high RECQL5-low RAD51 nuclear protein levels were significantly 
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associated with high grade, high mitosis and pleomorphism (ps<0.05) [Table 3]. Tumours with 
low RECQL5-low RAD51 nuclear protein levels were significantly associated with tubule 
formation, NPI>3.4 and ER/PR negativity (ps<0.5) [Table 3]. In univariate analysis, tumours 
with high RECQL5-low RAD51 nuclear protein levels were associated with poor breast cancer 
specific survival in the whole cohort (p=0.003) [Figure 2E]. In sub-group analysis, ER+ 
tumours with high RECQL5-low RAD51 nuclear protein levels were associated with poor 
breast cancer specific survival (p=0.010) [Figure 2F]. In ER- cohort, RECQL5-RAD51 co-
expression did not influence survival (p=0.628) [Supplementary Figure S1D]. We have 
previously shown a direct interaction between RECQL5 and Topoisomerase IIα (TOP2A) 
where RECQL5 specifically stimulated the decatenation activity of TOP2A (28). Tumours with 
low RECQL5-high TOPO2A were significantly associated with high grade, high mitotic index, 
de-differentiation tumour type, high risk NPI and PR negativity (Supplementary Table S6). 
In univariate analysis, RECQL5-TOPO2A co-expression did not influence survival 
(Supplementary Figures S1E, S1F, S1G) 
 
In multivariate analysis (Table 4), RECQL5-RAD51 co-expression remained statistically 
significant independent marker of prognosis (p=0.022) in the whole cohort. NPI and HER-2 
expression were other factors independently associated with breast cancer specific survival (ps 
0.001 and 0.0001 respectively).  In the ER+ sub-group, RECQL5-RAD51 co-expression was 
of borderline significance (p=0.07), but not in the ER- sub-group (p=0.172).   
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DISCUSSION 
 
RECQL5 is a key member of the RecQ family of DNA helicases (1-4). RECQL5 is a 
multifunctional protein with roles in DNA replication, chromosomal segregation, DNA repair 
(including homologous recombination, single strand break repair and base excision repair) and 
transcription. Emerging pre-clinical evidence suggests that RECQL5 is a tumour suppressor. 
RECQL5 deficient mice are predisposed to lymphomas and solid tumours including breast 
tumours (1-4). In humans, polymorphisms within the RECQL5 gene may predispose an 
individual to cancer including: osteosarcomas, laryngeal carcinomas and breast cancers (29-
32). In a recent study in colorectal cancers, low RECQL5 expression was observed at the 
mRNA and protein levels (19).  The authors concluded that RECQL5 deficiency may 
predispose to colorectal cancer. However, the study had several limitations, including a small 
cohort and lack of clear evidence of clinicopathological associations or survival outcomes (19).  
 
The clinicopathological significance of RECQL5 in sporadic breast cancer is unknown. In the 
current study we have comprehensively evaluated RECQL5, and unravelled its complex role 
in breast cancers. At the mRNA level, we observed high expression in 34% of tumours. High 
RECQL5 mRNA expression was significantly associated with aggressive phenotypes and 
adverse survival. The prognostic significance was particularly pronounced in ER+ sub-group, 
supporting the observation that high RECQL5 mRNA expression was more likely in 
ER+/HER2 -/high proliferation Geneufu sub-type tumours. At the protein level, we observed 
high RECQL5 levels in 53.7% of breast cancers. In contrast to mRNA expression data, 
although low RECQL5 expression was associated with aggressive phenotype, RECQL5 
protein alone did not influence survival outcomes in patients.  The data suggest that RECQL5 
may be subjected to complex post-transcriptional regulation. Another possibility is that the 
complex role of RECQL5 may operate in the context of RAD51. RECQL5 directly interacts 
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with RAD51 (9) and the anti-recombinogenic role of RECQL5 may be active through 
disruption of RAD51 mediated presynaptic filament formation during HR (33). Therefore, we 
conducted RECQL5-RAD51 co-expression studies and observed that tumours with high 
RECQL5/low RAD51 not only manifest aggressive phenotypes but were also associated with 
poor survival. In sub-group studies, similar to mRNA data, the prognostic significance was 
more pronounced in ER+ breast cancer but not in ER- tumours. Consistent with high RECQL5 
being associated with aggressive phenotypes, over expression of RECQL5 in the normal breast 
cell line MCF10A increased proliferation. Interestingly RAD51 is reported as having relatively 
low expression in MCF10A cells (34)and the functional relationship between RECQL5, 
RAD51, proliferation, recombination and tumourigenesis will be the subject of future 
investigations. Taken together, the data provides the first clinical evidence that RECQL5 may 
influence breast cancer pathogenesis.  
 
RECQL5 interacts with and is a general transcription elongation factor for RNA Pol II (2, 17, 
18). Loss of RECQL5 leads to a genome-wide increase in the average rate of gene transcription, 
transcriptional stress and recombination (17) suggesting RECQL5 has a function in resolving 
such stress. RNA polymerases generate positive supercoiling ahead of the transcription 
apparatus, which in turn feeds back to reduce the processional rate of RNA polymerase. 
Topoisomerases are ubiquitous enzymes that remove supercoiling and therefore are required 
for normal transcription elongation. Specifically, type II topoisomerases generate transient 
protein-concealed double strand breaks while removing torsional stress from the DNA and 
collisions with the transcription apparatus can convert these protein-DNA complexes into 
permanent DNA strand breaks (35). Previously, we showed a direct interaction between 
RECQL5 and Topoisomerase IIα (TOP2A) specifically stimulated the decatenation activity of 
TOP2A (28). TOP2A expression is a marker for proliferation and has been analyzed in a 
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number of breast cancer studies in part because it lies in close proximity to the HER2 gene on 
chromosome 17.  Therefore, we were interested in evaluating if there were any expression 
correlations between RECQL5, which also resides on chromosome 17 (17q25.1), and TOP2A 
expression in our breast cancer cohorts. Interestingly, high grade tumours are more often scored 
as RECQL5- and TOP2A+, than any other expression pattern. This may reflect the fact that 
loss of RECQL5 promotes transcriptional stress. Additionally, while TOP2A is known as a 
marker for proliferation, loss of RECQL5 may make these cells more dependent on TOP2A to 
relieve transcriptional stress. Thus in this subgroup of patients, it would be interesting to 
evaluate the efficacy of topoisomerase targeted therapies, if in fact these tumours are more 
dependent on topoisomerase activities than other tumour types cells.   
In conclusion, our data provides evidence that RECQL5 could be a promising biomarker in 
breast cancer and needs further investigation as a potential drug target.  
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Table 1: Association between RecQL5 mRNA expression and clinico-pathologic variables in 
METABRIC cohort. 
 
 
 
 
VARIABLE 
 
 
RECQL5 mRNA Expression  
 
 
 P Values 
Low High 
Unadjusted Adjusted 
N(%) N (%) 
 
A) Pathological    Parameters 
Lymph node stage  
Negative 684(52.6%) 351(52.5%) 0.990 
 
25.74 
 
Positive (1-3) 207(15.9%) 107(15.9%) 
Positive (>3) 409(31.5%) 213(31.7%) 
Grade 
G1 129(10.3%) 40(6.2%) 0.007 0.023 
G2 512(41.0%) 258(40.2%) 
G3 607(48.6%) 343(53.5%) 
Tumour Size (cm) 
T 1a+b(1.0) 61(4.7%) 31(4.7%) 0.097 0.157 
T 1c(>1.0-2.0) 532(41.0%) 234(35.6%) 
T2 (>2.0-5) 639(49.2%) 362(55.0%) 
T3 (>5) 67(68.4%) 31(31.6%) 
NPI 
≤ 3.4 461(35.3%) 219(32.6%) 0.238 0.269 
>3.4 137(64.7%) 1160(67.4%) 
 
Her2 overexpression (No)  1159(88.7%) 573(85.4%) 0.032 0.075 
                              (Yes) 147(11.3%) 98(14.6%) 
Triple negative          (No)        1079(82.6) 581 (88.6) 0.023 0.066 
                               (Yes)  227(17.4) 90(13.4) 
ER                   (Negative) 322(24.7%) 148(22.1%) 0.199 0.246 
                       (Positive) 984(75.3%)  523(77.9%) 
PgR                  (Negative) 603(46.2%) 333(49.6%) 0.145 0.188 
                         (Positive) 703(53.8%) 338(50.4%) 
Genefu subtype 
ER-/Her-2 negative 110(16.3%) 40(12.6%) 0.129 0.186 
ER+/Her-2 negative/high 
proliferation 
229(33.9%) 137(43.1%) 0.005 0.018 
ER+/Her-2 negative/low 
proliferation 
265(39.1%) 103(32.4%) 0.038 0.082 
Her-2 positive 72(10.7%) 38(11.9%) 0.543 0.564 
PAM50 subtype 
PAM50.Her2 130(11.2%) 108(17.6%) 1.5X10-4 0.0008 
PAM50.Basal   233(20.1%) 97(15.8%) 0.029 0.075 
PAM50.LumA 488(42.1%) 227(37.1%) 0.042 0.084 
PAM50.LumB 309(26.6%) 180(29.4%) 0.214 0.252 
IntClust subgroups 
24 
 
intClust.1 49(3.8%) 88(13.1%) 8.3X10-15 0.00001 
intClust.2 55(4.2%) 17(2.5%) 0.059 0.102 
intClust.3  221(16.9%) 69(10.3%) 7.8X10-5 0.0005 
intClust.4 267(20.4%) 76(11.3%) 3.9X10-7 0.00001 
intClust.5 120(63.5%) 69(36.5%) 0.433 0.469 
intClust.6 50(3.8%) 36(5.4%) 0.113 0.172 
intClust.7 113(8.7%) 40.2(11.3%) 0.056 0.104 
intClust.8 187(14.3) 113(16.8%) 0.139 0.191 
intClust.9 74(5.7%) 72(10.7%)   4.6X10-5 0.0004 
intClust.10 170(13.0%) 55(8.2%) 0.001 0.0043 
Bold = Statistically significant;HER2: human epidermal growth factor receptor 2; ER: 
oestrogen receptor; PgR: progesterone receptor;Triple negative: ER-/PgR-/HER2- . Adjusted 
p values were calculated using Benjamini-Hochberg false discovery rate method to adjust for 
multple testing. 
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Table 2. Multivariate analysis of RECQL5 mRNA expression in breast cancer 
 P-Value Risk Ratio 95% CI for Risk Ratio 
Lower Upper 
Breast Cancer Specific Survival (Whole Cohort) 
Grade 0.000004 1.447429 1.237421 1.693079 
Size (Cm) 0.000001 1.121003 1.076755 1.167069 
LN Status 0.000001 1.875371 1.666800 2.110040 
RECQL5 mRNA expression 0.023530 1.223718 1.027549 1.457337 
Breast Cancer Specific Survival (ER+ Cohort) 
Grade  
0.0002 1.411263 1.176981 1.692178 
Size (Cm) 
0.000001 1.180525 1.123389 1.240566 
LN Status 
0.000001 1.822326 1.578493 2.103825 
RECQL5 mRNA expression 0.045 
1.242008 1.004707 1.535359 
Breast Cancer Specific Survival (ER- Cohort) 
Grade 
0.968564 1.008054 0.676448 1.502217 
Size (Cm) 
0.239188 1.046124 0.970452 1.127695 
LN Status 
0.000001 1.908038 1.539252 2.365181 
RECQL5 mRNA expression 
0.635591 1.078023 0.790092 1.470886 
 
Bold: Statistically significant; HR: Hazard Ratio; CI: Confidence interval; LN: Lymph node 
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Table 3.  RECQL5 – RAD51 protein co-expression and breast cancer  
 
   
 
                    VARIABLE 
 
RECQL5 and RAD51 protein  
co-expression 
 
 
 
P- value 
(Unadjuste
d) 
 
 
P -Value 
(Adjusted
) RQ5n-
/RAD51n
- 
N (%) 
RQ5n+/ 
RAD51n- 
N (%) 
 
RQ5n-/ 
RAD51n
+ 
N (%) 
 
RQ5n+/ 
RAD51n+ 
N% 
A) Pathological    Parameters 
Tumour Size  
 ≤1cm 
 >1-2cm 
 >2-5cm 
>5cm 
 
 12 (6.8) 
77 (43.8) 
84 (47.7) 
3 (1.7) 
 
9 (5.8) 
65 (41.9) 
78 (50.3) 
3 (1.9) 
 
10 (7.6) 
73 (55.7) 
45 (34.4) 
3 (2.3) 
 
16 (8.6) 
107 (57.5) 
62 (33.3) 
1 (0.5) 
 
0.031 
 
0.045 
Tumour Stage                                 
1 
2 
3 
 
96 (54.5) 
64 (36.4) 
16 (9.1) 
 
83 (53.2) 
57 (36.5) 
16 (10.3) 
 
79 (60.3) 
44 (33.6) 
8 (6.1) 
 
112 (60.2) 
52 (28.0) 
22 (11.8) 
 
0.370 
 
0.401 
Tumour Grade                              
 G1 
 G2 
 G3 
  
13 (7.4) 
59 (33.5) 
104 (59.1) 
 
18 (11.5) 
38 (24.4) 
100 (64.1) 
 
14 (10.7) 
53 (40.5) 
64 (48.9) 
 
37 (19.9) 
73 (39.2) 
76 (40.9) 
 
4.1x10-5 
 
0.0005 
Mitotic Index  
M1 (low; mitoses < 10) 
M2 (medium; mitoses 10-
18) 
M3 (high; mitosis >18) 
 
45 (26.0) 
38 (22.0) 
90 (52.0) 
  
34 (22.5) 
28 (18.5) 
89 (58.9) 
 
41 (31.5) 
24 (18.5) 
65 (50.0) 
 
72 (40.0) 
38 (21.1) 
70 (38.9) 
 
0.008 
 
0.017 
Tubule Formation                          
1 (>75% definite tubule) 
2 (10%-75% definite tubule) 
3 (<10% definite tubule) 
5 (2.9) 
45 (26.0) 
123 (71.1) 
 
2 (1.3) 
49 (32.5) 
100 (66.2) 
 
7 (5.4) 
43 (33.1) 
80 (61.5) 
 
7 (3.9) 
75 (41.7) 
98 (54.4) 
 
0.025 
 
0.046 
Pleomorphism                                
1 (small-regular uniform) 
2 (Moderate variation) 
3 (Marked variation) 
 
0 (0.0) 
61 (35.5) 
111 (64.5) 
 
1 (0.7) 
42 (27.8) 
108 (71.5) 
 
2 (1.6) 
48 (37.2) 
79 (61.2) 
 
2 (1.1) 
82 (45.6) 
96 (53.3) 
 
0.027 
 
0.043 
Tumour Type                
IDC-NST 
Tubular Carcinoma 
Medullary Carcinoma 
ILC 
Others 
 
121 (69.9) 
21 (12.1) 
7 (4.0) 
14 (8.1) 
3 (1.7) 
 
113 (72.4) 
22 (14.1) 
2 (1.3) 
8 (5.1) 
1 (0.6) 
 
75 (58.1) 
27 (20.9) 
3 (2.3) 
13 (10.1) 
0 (0.0) 
 
102 (55.1) 
50 (27.0) 
0 (0.0) 
20 (10.8) 
1 (0.5) 
 
0.002 
 
0.005 
Lymph Node Status                   
Negative 
Positive (1-3) 
Positive (>3) 
81 (54.4) 
56 (37.6) 
12 (8.1) 
 
69 (51.1) 
54 (40.0) 
12 (8.9) 
 
72 (60.0) 
44 (36.7) 
4 (3.3) 
 
97 (58.4) 
53 (31.9) 
16 (9.6) 
 
0.353 
 
0.417 
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B) Aggressive Phenotype 
Her2 overexpression                     
No 
Yes 
153 (87.4) 
22 (12.6) 
 
123 (80.4) 
30 (19.6) 
 
105 (81.4) 
24 (18.6) 
 
159 (88.3) 
21 (11.7) 
 
0.105 
 
0.136 
Triple Negative Phenotype               
No 
Yes 
149 (84.7) 
27 (15.3) 
 
130 (83.3) 
26 (16.7) 
 
115 (87.8) 
16 (12.2) 
 
151 (81.2) 
35 (18.8) 
 
0.457 
 
5.94 
NPI           
≤3.4 
>3.4 
 
31 (18.3) 
138 (81.7) 
 
31 (21.2) 
115 (78.8) 
 
34 (27.4) 
90 (72.6) 
 
 
68 (38.4) 
109 (61.6) 
 
1.1x10-4 
 
0.0005 
C) Hormone Receptors 
ER               
Negative 
Positive 
 
60 (35.1) 
111 (64.9) 
 
53 (34.9) 
99 (65.1) 
 
32 (25.4) 
94 (74.6) 
 
28 (15.7) 
150 (84.3) 
 
7.6x10-5 
 
0.0005 
PgR                                   
Negative 
Positive 
 
91 (54.5) 
76 (45.5) 
 
77 (52.0) 
71 (48.0) 
 
49 (39.5) 
75 (60.5) 
 
63 (35.6) 
114 (64.4) 
 
0.001 
 
0.003 
Bold = Statistically significant; HER2: human epidermal growth factor receptor 2; ER: 
oestrogen receptor; PgR: progesterone receptor; Triple negative: ER-/PgR-/HER2- . Adjusted 
p values were calculated using Benjamini-Hochberg false discovery rate method to adjust for 
multple testing.  
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Table 4. Multivariate analysis of RECQL5-RAD51 protein co-expression in breast cancer 
 
 
 
 
  
 B P value Exp (B) 
95.0% CI for Exp (B) 
Lower Upper 
Breast Cancer Specific Survival in the whole cohort 
 
 
RECQL5-RAD51 co-expression 
       
       -0.069 
 
0.022 
 
0.934 
 
0.880 
 
0.990 
NPI 0.769 0.001 2.158 1.378 3.379 
ER Status 0.293 0.097 1.340 .949 1.893 
HER2 Status 0.728 0.0001 2.071 1.432 2.994 
  Breast Cancer Specific Survival in the ER+ cohort 
 
  RECQL5-RAD51 co-expression -0.063 0.073 0.939 0.876 1.006 
   NPI 0.784 0.001 2.190 1.376 3.484 
  HER2 Status          0.848 0.001 2.335 1.448 3.767 
  Breast Cancer Specific Survival in the ER- cohort 
 
RECQL5-RAD51 co-expression -0.081 0.172 0.923 0.822 1.036 
NPI 0.651 0.519 1.917 0.265 13.882 
HER2 Status 0.551 0.057 1.735 0.984 3.062 
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Figure legends 
 
Figure 1.  A. RECQL5 mRNA expression in breast cancer cell lines. B. Kaplan Meier curves 
showing BCSS (Breast cancer specific survival) based on RECQL5 mRNA expression in the 
whole cohort C. Kaplan Meier curves showing BCSS (Breast cancer specific survival) based 
on RECQL5 mRNA expression in ER+ cohort; D. Kaplan Meier curves showing BCSS (Breast 
cancer specific survival) based on RECQL5 mRNA expression in ER+ cohort that had 
endocrine therapy; E. Kaplan Meier curves showing BCSS (Breast cancer specific survival) 
based on RECQL5  mRNA expression in ER- cohort. F. Kaplan Meier curves showing BCSS 
(Breast cancer specific survival) based on RECQL5 mRNA expression in ER- cohort that had 
chemotherapy. 
 
Figure 2. A1. Western blot of RECQL5 expression in breast cancer cell lines. A2. MCF10A 
breast cells were transfected with RECQL5 or empty vector and. Extracts were made 48 h 
post transfection and western blotted for RECQL5. RECQL5 level in MCF7 cells is shown 
for comparison.  B. MCF10A breast cells were transfected with RECQL5 or empty vector 
and cell number counted every 24 h. Mean and standard deviation are shown for 3 
independent repeats. ** indicates a statistical significance of P<0.01 at 72 h using Student’s 
T.Test. C. Western blot of RECQL5 expression in MCF-7 (RECQL5 wild-type) and MCF-7 
RECQL5 knock down cell line. D. Microphotograph of RECQL5 protein expression in breast 
tumours.  E. Kaplan Meier curves showing BCSS based on RECQL5-RAD51 co-expression 
in the whole cohort. F. Kaplan Meier curves showing BCSS based on RECQL5-RAD51 co-
expression in ER+ cohort.  
 
 
